References
- Takahashi E, Nakamura S. Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53(1):1–8. doi:https://doi.org/10.3960/jslrt.53.1.
- Emile J-F, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127(22):2672–2681. doi:https://doi.org/10.1182/blood-2016-01-690636.
- Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003;27(5):579–593. doi:https://doi.org/10.1097/00000478-200305000-00003.
- Jain P, Surrey LF, Straka J, et al. BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatr Blood Cancer. 2021:e28933. doi:https://doi.org/10.1002/pbc.28933.
- Picarsic J, Jaffe R. Pathology of histiocytic disorders and neoplasms and related disorders. In: Abla O, Janka G, eds. Histiocytic Disorders. Cham: Springer International Publishing; 2018:3–50. doi:https://doi.org/10.1007/978-3-319-59632-7_1.
- Liu DJ, Rullo J, Kratky V, Farmer J. Histiocytic sarcoma of the eyelid. Saudi J Ophthalmol. 2019;33(3):300–303. doi:https://doi.org/10.1016/j.sjopt.2019.07.001.
- Aakalu VK, Patel RM, Lim J, Setabutr P. Orbital histiocytic sarcoma in a 2-year-old child. Ophthalmic Plast Reconstr Surg. 2014;30(6):e143–e145. doi:https://doi.org/10.1097/IOP.0b013e3182a74e3b.
- Cheng DT, Mitchell TN, Zehir A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251–264. doi:https://doi.org/10.1016/j.jmoldx.2014.12.006.
- Koren J, Matecek L, Zamecnik M. Mitotically active deep juvenile xanthogranuloma. Ann Diagn Pathol. 2010;14(1):36–40. doi:https://doi.org/10.1016/j.anndiagpath.2009.09.004.
- Nakatani T, Morimoto A, Kato R, et al. Successful treatment of congenital systemic juvenile xanthogranuloma with Langerhans cell histiocytosis-based chemotherapy. J Pediatr Hematol Oncol. 2004;26(6):371–374. doi:https://doi.org/10.1097/00043426-200406000-00007.
- Chiba K, Aihara Y, Eguchi S, et al. Diagnostic and management difficulties in a case of multiple intracranial juvenile xanthogranuloma. Childs Nerv Syst. 2013;29(6):1039–1045. doi:https://doi.org/10.1007/s00381-013-2100-1.
- Durham BH, Lopez-Rodrigo E, Abramson DH, et al. Activating mutations in CSF1R and additional receptor tyrosine kinases in sporadic and familial histiocytic neoplasms. Blood. 2018;132(Supplement 1):49–49. doi:https://doi.org/10.1182/blood-2018-99-114248.
- Jacobsen E, Abla O, Visser J. Malignant Histiocytoses. In: Abla O, Janka G, eds. Histiocytic Disorders. Cham: Springer International Publishing; 2018:361–381. doi:https://doi.org/10.1007/978-3-319-59632-7_20.